CLINICAL AND ECONOMIC ANALYSIS OF USING OF LONG ACTION ERYTHROPOES STIMULATED AGENTS FOR THE TREATMENT OF ANEMIA CKD V HD PATIENTS

Abstract

The article describes the ways to cost optimization of anemia treatment CKD - HD patients. Aims. dinical and economic analysis treatment of Anemia CKD VHD PTS with using long action Erythropoiesis Stimulating Agents (ESA). Methods. We calculated the true cost of anemia therapy with darbepoetin alfa compared to the methoxypolyethyleneglycol - epoetin beta. Results. It was established that average cost of therapy with methoxypolyethyleneglycol - epoetin beta was lower than darbepoetin alfa provided declared, wholesale or retail prices of25 - 60%. Conclusions. The methoxypolyethyleneglycol - epoetin beta haspharmacoeconomics advantages in comparison with the darbepoetin alfa in treatment of anemia CKD V HD patients.

Keywords

• pharmacoeconomic, anemia, ESA (erythropoes stimulated agents), hemodialysis, hemodiafiltration, pegilated erythropoietin - p, darbopoietin - a, Darbepoetin, long - сcontinuous erythropoietin receptor activator (CERA), chronic kidney diseases (CKD).